Department of Clinical Biochemistry, School of Public Health, Taishan Medical University.Shanghai Cancer Center and Shanghai Medical College, Fudan University.Shanghai Cancer Center and Shanghai Medical College, Fudan University wozhangsheng@hotmail.com.
刊名
Mol Cancer Ther
年份
2017
ISSN
1535-7163
分类号
616.992
摘要
Pneumonitis, a rare but potentially life-threatening adverse event in cancer patients receiving programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibitors, has been reported in case reports, clinical trials and retrospective studies. We performed a systematic review and meta-analysis to calculate the relative risk of pneumonitis associated with the use of PD-1/L1 inhibitors in randomized clinical trials (RCTs).We searched MEDLINE, Embase, the Cochrane Central Register of Controlle...更多
Pneumonitis, a rare but potentially life-threatening adverse event in cancer patients receiving programmed death-1 (PD-1) or programmed death ligand-1 (PD-L1) inhibitors, has been reported in case reports, clinical trials and retrospective studies. We performed a systematic review and meta-analysis to calculate the relative risk of pneumonitis associated with the use of PD-1/L1 inhibitors in randomized clinical trials (RCTs).We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, trial registers, conference proceedings, review articles, and reference lists of trial publications for all relevant randomized trials RCTs comparing PD-1/L1 inhibitors to control with available data on pneumonitis. The pooled incidence, relative risk and 95% CI were calculated using fixed effects or random effects model according to the heterogeneity of included trials. 12 RCTs were eligible for the meta-analysis, yielding a total of 5,775 patients, included in trials evaluating a PD-1 inhibitor; no eligible trials evaluated a PD-L1 inhibitor. The pooled incidence of all grade pneumonitis for patients treated with PD-1 inhibitors was 3.2% (95% CI, 2.3%-4.5%), and that of high grade pneumonitis was 1.1% (95% CI, 0.7%-1.7%). The relative risk of all grade and high grade pneumonitis was 4.36 (95% CI, 2.58-7.38) and 2.86 (95% CI, 1.30-6.31), respectively. In a sensitivity analysis, PD-1 inhibitors were also associated with significantly increased risk of pneumonitis per person-month (for all grade, RR=3.37, 95% CI, 1.97-5.76; for high grade, RR=2.25, 95% CI, 1.03-4.94). PD-1 inhibitors were associated with significant increase of all grade and high grade pneumonitis both per treatment episode and per person-month.收起
